



Multimeric Biotherapeutics, Inc.
("MultimericBio")
"Unlocking the potential of the TNF SuperFamily Ligands"

Antonella Vitiello becomes Principal Scientist of Multimeric Biotherapeutics, Inc.

Jan. 9, 2009, San Diego, CA – Multimeric Biotherapeutics, Inc. announces the appointment of Antonella Vitiello, D.Pharm. as its Principle Scientist. She is also a Founder of the company.

Dr. Vitiello is an immunologist with over 20 years of vaccine development experience. She received a Doctor of Pharmacy degree from the Universita' degli Studi di Pavia in Italy, and then went on to postdoctoral immunology training first in Pavia and then at The Scripps Research Institute in La Jolla, CA. She has served as a Principal Scientist at Johnson & Johnson and Director of Immunology at three vaccine companies (MediVas, Epimmune, and PaxVax, all in San Diego). She is the author of 45 papers and an inventor on 7 patents. Notably, Dr. Vitiello designed the first peptide-based HBV vaccine capable of inducing a cytotoxic T lymphocyte response in humans. At MultimericBio, Dr. Vitiello will develop the company's vaccine products and design its new research initiatives.

For further details, visit the company's website: www.multimericbio.com

About Multimeric Biotherapeutics, Inc.

Multimeric Biotherapeutics, Inc. is a biotech company focused on applying CD40L and other TNF SuperFamily ligands for the prevention and treatment of disease. It uses its novel technology to create next-generation vaccines and tumor immunotherapies. More information is available at www.multimericbio.com . Contact us at info@multimericbio.com